Alnylam Pharmaceuticals: Raymond James cuts to Outperform from Strong Buy, cuts target price to $315 from $420
ALNY•Raymond James lowered its rating on Alnylam Pharmaceuticals to Outperform from Strong Buy and cut its target price to $315 from $420.
Related News
State Street launches SPYMX mutual fund share class of S&P 500 ETF
STT•
Sienna Senior Living completes $170.7 million acquisition of Ottawa retirement residence
SNVVF•
Clarivate Plc: Morgan Stanley resumes coverage with underweight rating; target price $1.5
CLVT•
Oppenheimer raises Granite Construction target price to $185 from $180
GVA•
India bonds buckle for fourth straight month on oil's climb
TLT•